Mosanna Therapeutics Launches with $80 Million to Advance Novel Nighttime Nasal Spray for Obstructive Sleep Apnea
Series A funding to advance MOS118 through Phase 2 clinical trials Biotech veteran David Weber appointed CEO to drive clinical development Obstructive sleep apnea affects nearly 1 billion people globally, with the majority undiagnosed and underserved with current…